Daiichi Sankyo and AstraZeneca recently announced encouraging results from the TROPION-PanTumor03 Phase 2 trial, which examined the efficacy of DATROWAY® (datopotamab deruxtecan) in combination with rilvegostomig for patients suffering from metastatic urothelial cancer. The trial yielded a notable confirmed objective response rate of 68.2% and a substantial disease control rate of 95.5% among previously untreated patients deemed ineligible for cisplatin therapy. These findings were shared during a mini oral session at the 2025 European Society for Medical Oncology Congress.
Understanding the Trial’s Framework
In the trial, DATROWAY, a TROP2-directed antibody-drug conjugate developed through a collaboration between Daiichi Sankyo and AstraZeneca, was evaluated as a first-line and second-line treatment option. Specifically, the study focused on patients with locally advanced or metastatic urothelial cancer. The results from the first-line treatment group demonstrated a 68.2% confirmed objective response rate, with median progression-free survival rates not yet reached. Among the second-line treatment cohort, the confirmed response rate was lower at 38.9%, with a median progression-free survival of 12.5 months.
These initial results indicate a compelling potential for DATROWAY combined with rilvegostomig, a PD-1/TIGIT bispecific antibody from AstraZeneca, especially in a population that often faces limited therapeutic options.
Expert Insights on Treatment Options
Dr. Sun Young Rha, a leading oncologist from the Yonsei Cancer Center in Seoul, highlighted the critical need for effective therapies in treating metastatic urothelial cancer, emphasizing the limited options currently available for patients who progress after first-line therapies. He noted the significance of the high disease control rate observed in the trial, suggesting that the combination therapy could offer new hope in this challenging area of oncology.
The safety profile of the combination treatment was found to align with previous findings on each individual agent. Instances of grade 3 or higher treatment-related adverse events occurred in a minority of patients, with the most frequently observed events being increased amylase and neutropenia.
Next Steps in Clinical Development
Following the promising outcomes of TROPION-PanTumor03, Daiichi Sankyo has initiated the TROPION-Urothelial03 Phase 2/3 trial. This new study aims to further assess the effectiveness of DATROWAY combined with platinum-based chemotherapy in patients who have previously undergone treatment for metastatic urothelial carcinoma. Dr. Abderrahmane Laadem, head of late-stage oncology development at Daiichi Sankyo, remarked on the urgency for new therapies, given the low five-year survival rate for patients dealing with this type of cancer.
The TROPION program represents a robust effort to advance treatment options across various cancers, with more than 20 ongoing trials aimed at evaluating the efficacy and safety of DATROWAY in different settings. As such, the collaboration between Daiichi Sankyo and AstraZeneca continues to gain momentum, aiming to improve outcomes for patients facing difficult-to-treat malignancies.
For more information on these trials and the ongoing research in this field, interested parties can visit ClinicalTrials.gov.
Related
